![]() |
|
|
Vol. 295, Issue 2, 734-740, November 2000
Department of Pharmacy, Division of Biopharmaceutics and
Pharmacokinetics, Uppsala University, Uppsala, Sweden
Models of leukopenia after chemotherapy are mainly empirical. To
increase the derived models' potential of mechanistic understanding and extrapolation, more physiologically based models are being developed. To date, presented models cannot characterize the
often-observed rebound of leukocytes. Therefore, a model able to
describe the transient decrease and rebound in leukocytes was
developed. Three different dosing regimens of 5-fluorouracil were given
to rats. One group received a single dose of 127 mg/kg. The other two
groups received two and three injections of 63 mg/kg and 49 mg/kg,
respectively, with a 2-day interval. Leukocyte counts were followed for
23 to 25 days after the first dose. Plasma concentrations were
determined by high-performance liquid chromatography. Population
pharmacokinetic and pharmacodynamic models were developed using NONMEM.
5-Fluorouracil showed one-compartment disposition with capacity-limited
elimination. The 49-mg/kg dose injected on three occasions produced the
lowest leukocyte count (28% of baseline) and the most prominent
rebound of the schedules, despite the fact that the fractionated
regimens produced only 52 to 56% of the area under the
concentration-time curve from time 0 to infinity in the
single-dose group. The final semiphysiological model included two
5-fluorouracil-sensitive and two -insensitive transit compartments as
well as a compartment of circulating leukocytes. Second order rate
constants from the transit compartments and a negative feedback from
the circulating leukocytes to the input of the first sensitive
compartment characterized the pronounced changes in leukocyte counts. A
posterior predictive check as well as predictions into a new data set
showed that our model could well predict the schedule-dependent
leukopenic effects of 5-fluorouracil.
This article has been cited by other articles:
![]() |
M. Joerger, A. D.R. Huitema, D. J. Richel, C. Dittrich, N. Pavlidis, E. Briasoulis, J. B. Vermorken, E. Strocchi, A. Martoni, R. Sorio, et al. Population Pharmacokinetics and Pharmacodynamics of Paclitaxel and Carboplatin in Ovarian Cancer Patients: A Study by the European Organization for Research and Treatment of Cancer-Pharmacology and Molecular Mechanisms Group and New Drug Development Group Clin. Cancer Res., November 1, 2007; 13(21): 6410 - 6418. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. E. Friberg, A. Henningsson, H. Maas, L. Nguyen, and M. O. Karlsson Model of Chemotherapy-Induced Myelosuppression With Parameter Consistency Across Drugs J. Clin. Oncol., December 15, 2002; 20(24): 4713 - 4721. [Abstract] [Full Text] [PDF] |
||||